A Study of Japanese Rheumatoid Arthritis Participants
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and tolerability of 48 weeks
subcutaneous (SC) dosing with LY2127399 for participants who have participated in a prior
LY2127399 clinical study. At the end of the 48-week treatment period, participants will
participate in a 24-week follow-up period. Additional follow up after Week 72 may continue to
assess B-cell recovery.